Marker Therapeutics, Inc.
MRKR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MRKR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MRKR
Marker Therapeutics, Inc. is a clinical-stage biotechnology company developing multi-antigen recognizing T cell (MAR-T) therapies for oncology, with no approved products and a cash runway into Q2 2027.
Key risk: No commercial revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for Marker Therapeutics, Inc..
Marker Therapeutics, Inc. is a clinical-stage biotechnology company developing multi-antigen recognizing T cell (MAR-T) therapies for oncology, with no approved products and a cash runway into Q2 2027.
- Marker Therapeutics has no approved drug products and has not generated any commercial revenue from product sales [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company reported cash and equivalents of $11.9M, net loss of -$1.8M for the quarter, and shareholders' equity of $16.8M [sec].
- Net cash used in operating activities during the six months ended June 30, 2026 was $6.7 million, compared to $10.1 million in the prior year period [sec_mda · as of 2026-08-14].
- The company anticipates funding operations into the second quarter of 2027 based on current cash, cash equivalents, and restricted cash as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Marker Therapeutics plans to raise additional capital through common share issuances and grant funds to extend its cash runway beyond Q2 2027 [sec_mda · as of 2026-08-14].
What works
- Operating cash burn decreased: net cash used in operating activities for H1 2026 was $6.7M versus $10.1M in H1 2025, indicating improved cost management [sec_mda · as of 2026-08-14].
- The company has a cash runway into Q2 2027, providing a near-term operational horizon without immediate financing [sec_mda · as of 2026-08-14].
- Marker Therapeutics has a pipeline of MAR-T cell product candidates targeting multiple tumor antigens, which may offer a differentiated approach in adoptive cell therapy [sec_mda · as of 2026-03-18].
What to weigh
- The company has no approved products and no recurring revenue, relying entirely on capital raises and grants to fund operations [sec_mda · as of 2026-08-14].
- Substantial additional funding is required to continue clinical trials and potential commercialization, with no assurance of raising capital on attractive terms [sec_mda · as of 2025-11-13].
- If unable to raise capital, the company may be forced to delay, reduce, or eliminate its research and development activities [sec_mda · as of 2025-11-13].
- The company faces significant uncertainty in estimating future capital needs due to variable clinical trial costs and development timelines [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Marker Therapeutics has no approved drug products and no commercial revenue.
“To date, we have not generated any revenues from the commercial sale of approved drug products, and”
SEC MD&A · August 14, 2026
Cash runway extends into Q2 2027.
“we anticipate that we will be able to fund our operating expenses and capital expenditure requirements into the second quarter of 2027, assuming no additional grant funds are received.”
SEC MD&A · August 14, 2026
The company plans to raise additional capital through equity and grants.
“We currently plan to raise additional capital through the issuance of common shares and receive additional grant funds, which could enable us to fund our operating expenses and capital expenditure requirements beyond the secon”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- No commercial revenue — No approved products or recurring revenue; operations depend entirely on capital raises and grants [sec_mda · as of 2026-08-14].
- Cash runway limited to Q2 2027 — Current cash funds operations only into Q2 2027; additional capital needed to continue beyond [sec_mda · as of 2026-08-14].
- Uncertain future funding — No assurance of raising capital on attractive terms; may delay or reduce R&D if unable [sec_mda · as of 2025-11-13].
- Clinical and regulatory risk — Product candidates may fail in trials or not obtain regulatory approval; no revenue timeline [sec_mda · as of 2025-03-31].
What to watch
- Ability to raise additional capital through equity offerings or grants to extend cash runway beyond Q2 2027 [sec_mda · as of 2026-08-14].
- Progress of MAR-T cell product candidates in clinical trials, particularly any pivotal trial for lymphoma [sec_mda · as of 2025-11-13].
- Operating expense trends and cash burn rate in upcoming quarterly reports [sec_mda · as of 2026-08-14].
- Any regulatory milestones or partnership announcements that could provide non-dilutive funding [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Marker Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Marker Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
10.3 months
D/E 0.20 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$2.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 778,638 | $1.0M |
| renaissance technologies llc | 175,294 | $228K |
| geode capital management, llc | 160,910 | $209K |
| osaic holdings, inc. | 93,121 | $121K |
| vanguard fiduciary trust co | 87,269 | $113K |
| xtx topco ltd | 63,567 | $83K |
| two sigma investments, lp | 61,001 | $79K |
| susquehanna international group, llp | 48,780 | $63K |
| jane street group, llc | 36,303 | $47K |
| ubs group ag | 32,369 | $42K |
Showing top 10 of 32 institutional holders of Marker Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 1.4%
- Days to cover
- 1.2
- Shares short
- 190,658
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MRKR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Marker Therapeutics, Inc.?
Marker Therapeutics, Inc. is a clinical-stage biotechnology company developing multi-antigen recognizing T cell (MAR-T) therapies for oncology, with no approved products and a cash runway into Q2 2027.
What is Marker Therapeutics, Inc.'s lead drug candidate?
Marker Therapeutics, Inc.'s most advanced tracked candidate is mt-601 (Phase 1) for Non-Hodgkin Lymphoma, Adult.
Who is the CEO of Marker Therapeutics, Inc.?
Dr. Juan F. Vera M.D. is the chief executive officer of Marker Therapeutics, Inc. (MRKR).
Where is Marker Therapeutics, Inc. headquartered?
Marker Therapeutics, Inc. (MRKR) is headquartered in Houston, TX, United States.
What therapeutic areas does Marker Therapeutics, Inc. focus on?
Marker Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.